funnyangel-shutterstock-com-1

funnyangel / Shutterstock.com

18 May 2016Americas

PTAB gives green light to AbbVie IPR trial

The US Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) will review one of AbbVie’s patents covering its arthritis treatment drug Humira (adalimumab), following a challenge by drug maker Coherus Bioscience.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Preventative IP for preventative pharma healthcare

Court denies Regeneron bid to halt copy of blockbuster eye drug

Interview: Klaus Grabinski, UPC Court of Appeal president

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel

‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird

Sandoz wins $137.2m payout for lost profits in generic launch

Sanofi signs global rights deal to develop rare cancer therapy